产品名称
Milli-Mark 抗-Ki67抗体，克隆Ki-S5 APC偶联物, clone Ki-S5, Milli-Mark®, from mouse
biological source
mouse
conjugate
Allophycocyanin conjugate
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
Ki-S5, monoclonal
species reactivity
human
manufacturer/tradename
Milli-Mark®
technique(s)
flow cytometry: suitable
immunocytochemistry: suitable
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
isotype
IgG1
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... MKI67(4288)
Analysis Note
对照
刺激Jurkat细胞
刺激Jurkat细胞
通过Jurkat细胞的流式细胞仪评估。
Application
使用经验证可用于FC、IC、IH、FC、IH（P）的Milli-Mark抗Ki67抗体（克隆Ki-S5 APC偶联物）检测Ki67。
研究子类别
细胞周期，DNA 复制&修复
细胞周期，DNA 复制&修复
研究类别
信号传导
信号传导
Biochem/physiol Actions
抗体识别Ki67。
Disclaimer
除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
General description
Ki67抗原是与原型细胞周期相关的核蛋白，通过在活跃细胞周期的所有阶段（G1、S、G2和M阶段）的增殖细胞来表达。在静息（G0）细胞中不表达。Ki67抗体可用于确定肿瘤中的细胞生长分数（通过免疫组织化学定量确定总静息细胞数中Ki67阳性细胞数 = Ki67指数）。在肿瘤组织中，预后值与氚胸苷标记指数相当。低Ki67指数与组织学低级别肿瘤之间具有很强的相关性。Ki67通常用作细胞周期和增殖的标志物。Ki-S5抗体对增殖细胞的这种特异性可使其成为确定肿瘤增殖分数的有用工具，例如非霍奇金′淋巴瘤（Kreipe et al., 1993）、乳癌（Mauri et al., 1984）、卵巢肿瘤（Ballin et al., 1994）和前列腺癌。
实测分子量：345 & 395 kDa
Immunogen
来自人细胞系U937.50的核蛋白制剂。
Physical form
在含0.1％叠氮化钠和15 mg/mL BSA的PBS中的别藻蓝素（APC）偶联的纯化小鼠单克隆IgG1。
纯化的蛋白A
Preparation Note
自收到之日起，以未稀释的等分试样在2-8oC下可冷藏达6个月。避光保存。
Legal Information
MILLI-MARK is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Henrikki Mertaniemi et al.
Biomaterials, 82, 208-220 (2016-01-15)
Upon surgery, local inflammatory reactions and postoperative infections cause complications, morbidity, and mortality. Delivery of human adipose mesenchymal stem cells (hASC) into the wounds is an efficient and safe means to reduce inflammation and promote wound healing. However, administration of
Margarita Pustovalova et al.
International journal of molecular sciences, 21(9) (2020-05-14)
Radiation therapy is one of the main methods of treating patients with non-small cell lung cancer (NSCLC). However, the resistance of tumor cells to exposure remains the main factor that limits successful therapeutic outcome. To study the molecular/cellular mechanisms of
Xiao-Tong Lin et al.
eLife, 10 (2021-11-16)
Dysregulation of tumor-relevant proteins may contribute to human hepatocellular carcinoma (HCC) tumorigenesis. FBXO45 is an E3 ubiquitin ligase that is frequently elevated expression in human HCC. However, it remains unknown whether FBXO45 is associated with hepatocarcinogenesis and how to treat
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持